Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
Objectives:
The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens.
Design:
BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and optimized background therapy (OBT) in heavily treatment-experienced individuals failing antiretroviral therapy with limited treatment options (Randomized Cohort 1-2 and Nonrandomized Cohort 0 fully active antiretroviral classes).
Methods:
Virologic response rates (HIV-1 RNA
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research